Ligand Announces Third Quarter 2016 Earnings Release Date and Participation in the Stephens Fall Investment Conference
October 13 2016 - 9:00AM
Business Wire
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
announced today plans to report third quarter 2016 financial
results on November 3, 2016. Ligand’s CEO John Higgins, President
and COO Matt Foehr and CFO Matt Korenberg will host the conference
call. Ligand also announced participation in the upcoming Stephens
Fall Investment Conference.
Third Quarter Earnings Call
What: Ligand conference call to discuss
financial results and provide general business updates When:
Thursday, November 3, 2016 Time: 4:30 p.m. Eastern time
(1:30 p.m. Pacific time) Conference Call: (877) 407-4019
within the U.S. (201) 689-8337 outside the U.S. Passcode: Ligand
Webcast:
Live conference call webcast and replay
accessible at www.ligand.com
Investment Conference
Ligand executives are scheduled to participate in the upcoming
Stephens Fall Investment Conference in New York on Wednesday,
November 9, 2016 at 1:00 p.m. Eastern time (10:00 a.m. Pacific
time). John Higgins, CEO and Matt Korenberg, CFO will present for
Ligand. A live webcast will be accessible at www.ligand.com and
replay will be available for 30 days.
About Ligand Pharmaceuticals
Ligand is a biopharmaceutical company focused on developing or
acquiring technologies that help pharmaceutical companies discover
and develop medicines. Our business model creates value for
stockholders by providing a diversified portfolio of biotech and
pharmaceutical product revenue streams that are supported by an
efficient and low corporate cost structure. Our goal is to offer
investors an opportunity to participate in the promise of the
biotech industry in a profitable, diversified and lower-risk
business than a typical biotech company. Our business model is
based on doing what we do best: drug discovery, early-stage drug
development, product reformulation and partnering. We partner with
other pharmaceutical companies to leverage what they do best
(late-stage development, regulatory management and
commercialization) to ultimately generate our revenue. Ligand’s
Captisol® platform technology is a patent-protected, chemically
modified cyclodextrin with a structure designed to optimize the
solubility and stability of drugs. OmniAb® is a patent-protected
transgenic animal platform used in the discovery of fully human
mono-and bispecific therapeutic antibodies. Ligand has established
multiple alliances, licenses and other business relationships with
the world's leading pharmaceutical companies including Novartis,
Amgen, Merck, Pfizer, Celgene, Gilead, Janssen, Baxter
International and Eli Lilly.
Follow Ligand on Twitter @Ligand_LGND.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161013005218/en/
Ligand Pharmaceuticals IncorporatedTodd Pettingill(858)
550-7500investors@ligand.comorLHABruce Voss(310)
691-7100bvoss@lhai.com
Ligand Pharmaceuticals (NASDAQ:LGND)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ligand Pharmaceuticals (NASDAQ:LGND)
Historical Stock Chart
From Apr 2023 to Apr 2024